Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema

Mark D. Wewers, M. Anthony Casolaro, Stephanie E. Sellers, Sonia C. Swayze, Kathleen M. McPhaul, Janet T. Wittes, Ronald Crystal

Research output: Contribution to journalArticle

413 Citations (Scopus)

Abstract

In patients with alpha1-antitrypsin deficiency, the development of emphysema is believed to be caused by the unchecked action of proteases on lung tissue. We evaluated the feasibility, safety, and biochemical efficacy of intermittent infusions of alpha1-antitrypsin in the treatment of patients with alpha1-antitrypsin deficiency. Twenty-one patients were given 60 mg of active plasma-derived alpha1-antitrypsin per kilogram of body weight, once a week for up to six months. After a steady state had been reached, the group had trough serum levels of alpha1-antitrypsin of 126±1 mg per deciliter as compared with 30±1 mg per deciliter before treatment, and serum anti-neutrophil elastase capacities of 13.3±0.1 μM as compared with 5.4±0.1 μM. The alpha1-antitrypsin level in the epithelial-lining fluid of the lungs was 0.46±0.16 μM before treatment, and the anti-neutrophil elastase capacity was 0.81 ±0.13 μM. Six days after infusion, alpha1-antitrypsin levels (1.89±0.17 μM) and anti-neutrophil elastase capacities (1.65±0.13 μM) in the lining fluid were significantly increased (P<0.0001). Because of the chronicity of the disorder and the lack of sensitive measures of lung destruction, the clinical efficacy of this therapy could not be studied rigorously. No changes in lung function were observed in our patients over six months of treatment. The only important adverse reactions to the 507 infusions were four episodes of self-limited fever. This study demonstrates that infusions of alpha1-antitrypsin derived from plasma are safe and can reverse the biochemical abnormalities in serum and lung fluid that characterize this disorder. Together with lifetime avoidance of cigarette smoking, replacement therapy with alpharantitrypsin may be a logical approach to long-term medical treatment. (N Engl J Med 1987; 316:1055–62.), EMPHYSEMA is a chronic disorder of the lower respiratory tract, characterized by enlargement of the air spaces distal to the terminal bronchioles that results from destruction of the alveolar walls.1 , 2 The purest form of emphysema is found in adults with alpha1-antitrypsin deficiency, an autosomal recessive disorder characterized by serum alpha1-antitrypsin levels below 35 percent of normal and panacinar emphysema that presents in the third to fourth decades.3 4 5 6 7 8 9 10 Overall, alpha1-antitrypsin deficiency is responsible for approximately 2 percent of all cases of emphysema in the United States.5 , 11 Typically, a patient is affected in middle age with moderate to severe emphysema that is…

Original languageEnglish
Pages (from-to)1055-1062
Number of pages8
JournalNew England Journal of Medicine
Volume316
Issue number17
DOIs
Publication statusPublished - 23 Apr 1987
Externally publishedYes

Fingerprint

Emphysema
Leukocyte Elastase
Lung
Serum
Therapeutics
Bronchioles
Pulmonary Emphysema
Respiratory System
Peptide Hydrolases
Fever
Smoking
Air
Body Weight
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wewers, M. D., Casolaro, M. A., Sellers, S. E., Swayze, S. C., McPhaul, K. M., Wittes, J. T., & Crystal, R. (1987). Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema. New England Journal of Medicine, 316(17), 1055-1062. https://doi.org/10.1056/NEJM198704233161704

Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema. / Wewers, Mark D.; Casolaro, M. Anthony; Sellers, Stephanie E.; Swayze, Sonia C.; McPhaul, Kathleen M.; Wittes, Janet T.; Crystal, Ronald.

In: New England Journal of Medicine, Vol. 316, No. 17, 23.04.1987, p. 1055-1062.

Research output: Contribution to journalArticle

Wewers, MD, Casolaro, MA, Sellers, SE, Swayze, SC, McPhaul, KM, Wittes, JT & Crystal, R 1987, 'Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema', New England Journal of Medicine, vol. 316, no. 17, pp. 1055-1062. https://doi.org/10.1056/NEJM198704233161704
Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT et al. Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema. New England Journal of Medicine. 1987 Apr 23;316(17):1055-1062. https://doi.org/10.1056/NEJM198704233161704
Wewers, Mark D. ; Casolaro, M. Anthony ; Sellers, Stephanie E. ; Swayze, Sonia C. ; McPhaul, Kathleen M. ; Wittes, Janet T. ; Crystal, Ronald. / Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema. In: New England Journal of Medicine. 1987 ; Vol. 316, No. 17. pp. 1055-1062.
@article{a26c66eb0f73428d8810ad43f7bf2373,
title = "Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema",
abstract = "In patients with alpha1-antitrypsin deficiency, the development of emphysema is believed to be caused by the unchecked action of proteases on lung tissue. We evaluated the feasibility, safety, and biochemical efficacy of intermittent infusions of alpha1-antitrypsin in the treatment of patients with alpha1-antitrypsin deficiency. Twenty-one patients were given 60 mg of active plasma-derived alpha1-antitrypsin per kilogram of body weight, once a week for up to six months. After a steady state had been reached, the group had trough serum levels of alpha1-antitrypsin of 126±1 mg per deciliter as compared with 30±1 mg per deciliter before treatment, and serum anti-neutrophil elastase capacities of 13.3±0.1 μM as compared with 5.4±0.1 μM. The alpha1-antitrypsin level in the epithelial-lining fluid of the lungs was 0.46±0.16 μM before treatment, and the anti-neutrophil elastase capacity was 0.81 ±0.13 μM. Six days after infusion, alpha1-antitrypsin levels (1.89±0.17 μM) and anti-neutrophil elastase capacities (1.65±0.13 μM) in the lining fluid were significantly increased (P<0.0001). Because of the chronicity of the disorder and the lack of sensitive measures of lung destruction, the clinical efficacy of this therapy could not be studied rigorously. No changes in lung function were observed in our patients over six months of treatment. The only important adverse reactions to the 507 infusions were four episodes of self-limited fever. This study demonstrates that infusions of alpha1-antitrypsin derived from plasma are safe and can reverse the biochemical abnormalities in serum and lung fluid that characterize this disorder. Together with lifetime avoidance of cigarette smoking, replacement therapy with alpharantitrypsin may be a logical approach to long-term medical treatment. (N Engl J Med 1987; 316:1055–62.), EMPHYSEMA is a chronic disorder of the lower respiratory tract, characterized by enlargement of the air spaces distal to the terminal bronchioles that results from destruction of the alveolar walls.1 , 2 The purest form of emphysema is found in adults with alpha1-antitrypsin deficiency, an autosomal recessive disorder characterized by serum alpha1-antitrypsin levels below 35 percent of normal and panacinar emphysema that presents in the third to fourth decades.3 4 5 6 7 8 9 10 Overall, alpha1-antitrypsin deficiency is responsible for approximately 2 percent of all cases of emphysema in the United States.5 , 11 Typically, a patient is affected in middle age with moderate to severe emphysema that is…",
author = "Wewers, {Mark D.} and Casolaro, {M. Anthony} and Sellers, {Stephanie E.} and Swayze, {Sonia C.} and McPhaul, {Kathleen M.} and Wittes, {Janet T.} and Ronald Crystal",
year = "1987",
month = "4",
day = "23",
doi = "10.1056/NEJM198704233161704",
language = "English",
volume = "316",
pages = "1055--1062",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "17",

}

TY - JOUR

T1 - Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema

AU - Wewers, Mark D.

AU - Casolaro, M. Anthony

AU - Sellers, Stephanie E.

AU - Swayze, Sonia C.

AU - McPhaul, Kathleen M.

AU - Wittes, Janet T.

AU - Crystal, Ronald

PY - 1987/4/23

Y1 - 1987/4/23

N2 - In patients with alpha1-antitrypsin deficiency, the development of emphysema is believed to be caused by the unchecked action of proteases on lung tissue. We evaluated the feasibility, safety, and biochemical efficacy of intermittent infusions of alpha1-antitrypsin in the treatment of patients with alpha1-antitrypsin deficiency. Twenty-one patients were given 60 mg of active plasma-derived alpha1-antitrypsin per kilogram of body weight, once a week for up to six months. After a steady state had been reached, the group had trough serum levels of alpha1-antitrypsin of 126±1 mg per deciliter as compared with 30±1 mg per deciliter before treatment, and serum anti-neutrophil elastase capacities of 13.3±0.1 μM as compared with 5.4±0.1 μM. The alpha1-antitrypsin level in the epithelial-lining fluid of the lungs was 0.46±0.16 μM before treatment, and the anti-neutrophil elastase capacity was 0.81 ±0.13 μM. Six days after infusion, alpha1-antitrypsin levels (1.89±0.17 μM) and anti-neutrophil elastase capacities (1.65±0.13 μM) in the lining fluid were significantly increased (P<0.0001). Because of the chronicity of the disorder and the lack of sensitive measures of lung destruction, the clinical efficacy of this therapy could not be studied rigorously. No changes in lung function were observed in our patients over six months of treatment. The only important adverse reactions to the 507 infusions were four episodes of self-limited fever. This study demonstrates that infusions of alpha1-antitrypsin derived from plasma are safe and can reverse the biochemical abnormalities in serum and lung fluid that characterize this disorder. Together with lifetime avoidance of cigarette smoking, replacement therapy with alpharantitrypsin may be a logical approach to long-term medical treatment. (N Engl J Med 1987; 316:1055–62.), EMPHYSEMA is a chronic disorder of the lower respiratory tract, characterized by enlargement of the air spaces distal to the terminal bronchioles that results from destruction of the alveolar walls.1 , 2 The purest form of emphysema is found in adults with alpha1-antitrypsin deficiency, an autosomal recessive disorder characterized by serum alpha1-antitrypsin levels below 35 percent of normal and panacinar emphysema that presents in the third to fourth decades.3 4 5 6 7 8 9 10 Overall, alpha1-antitrypsin deficiency is responsible for approximately 2 percent of all cases of emphysema in the United States.5 , 11 Typically, a patient is affected in middle age with moderate to severe emphysema that is…

AB - In patients with alpha1-antitrypsin deficiency, the development of emphysema is believed to be caused by the unchecked action of proteases on lung tissue. We evaluated the feasibility, safety, and biochemical efficacy of intermittent infusions of alpha1-antitrypsin in the treatment of patients with alpha1-antitrypsin deficiency. Twenty-one patients were given 60 mg of active plasma-derived alpha1-antitrypsin per kilogram of body weight, once a week for up to six months. After a steady state had been reached, the group had trough serum levels of alpha1-antitrypsin of 126±1 mg per deciliter as compared with 30±1 mg per deciliter before treatment, and serum anti-neutrophil elastase capacities of 13.3±0.1 μM as compared with 5.4±0.1 μM. The alpha1-antitrypsin level in the epithelial-lining fluid of the lungs was 0.46±0.16 μM before treatment, and the anti-neutrophil elastase capacity was 0.81 ±0.13 μM. Six days after infusion, alpha1-antitrypsin levels (1.89±0.17 μM) and anti-neutrophil elastase capacities (1.65±0.13 μM) in the lining fluid were significantly increased (P<0.0001). Because of the chronicity of the disorder and the lack of sensitive measures of lung destruction, the clinical efficacy of this therapy could not be studied rigorously. No changes in lung function were observed in our patients over six months of treatment. The only important adverse reactions to the 507 infusions were four episodes of self-limited fever. This study demonstrates that infusions of alpha1-antitrypsin derived from plasma are safe and can reverse the biochemical abnormalities in serum and lung fluid that characterize this disorder. Together with lifetime avoidance of cigarette smoking, replacement therapy with alpharantitrypsin may be a logical approach to long-term medical treatment. (N Engl J Med 1987; 316:1055–62.), EMPHYSEMA is a chronic disorder of the lower respiratory tract, characterized by enlargement of the air spaces distal to the terminal bronchioles that results from destruction of the alveolar walls.1 , 2 The purest form of emphysema is found in adults with alpha1-antitrypsin deficiency, an autosomal recessive disorder characterized by serum alpha1-antitrypsin levels below 35 percent of normal and panacinar emphysema that presents in the third to fourth decades.3 4 5 6 7 8 9 10 Overall, alpha1-antitrypsin deficiency is responsible for approximately 2 percent of all cases of emphysema in the United States.5 , 11 Typically, a patient is affected in middle age with moderate to severe emphysema that is…

UR - http://www.scopus.com/inward/record.url?scp=0023148995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023148995&partnerID=8YFLogxK

U2 - 10.1056/NEJM198704233161704

DO - 10.1056/NEJM198704233161704

M3 - Article

VL - 316

SP - 1055

EP - 1062

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -